Liquid Chromatography-Tandem Mass Spectrometry of a New PPARα/γ Dual Agonist PAR-5359 in Rat Plasma

다국어 초록 (Multilingual Abstract)

PAR-5359, 3-(4-{2-[4-(4-Chloro-phenyl)-3,6-dihydro-2H-pyridin-1-yl]-ethoxy}-phenyl)-2-ethoxypropionic acid, is a well-balanced PPARα/γ dual agonist with the excellent antihyperglycemic and hypolipidemic activities. A reliable, selective and sensitive high-performance liquid chromatography
with electrospray ionization tandem mass spectrometry was developed for the
determination of PAR-5359 in rat plasma. PAR-5359 was twice extracted from rat plasma using methyl tert-butyl ether at neutral pH. The analytes were separated on an Allure Biphenyl column with the mobile phase of 78% methanol in 10 mM ammonium formate (pH 3.0) and detected by tandem mass spectrometry in the selective reaction monitoring mode. The calibration
curve was linear (r = 0.9993) over the concentration range of 2.00-1000.0 ng/mL and the lower limit of quantification was 2.00 ng/mL using 50 μL plasma sample. The coefficient of variation and relative error at four QC levels were 1.2 to 12.3% and -2.5 to 6.3%, respectively. The present method was successfully applied to the pharmacokinetic study of PAR-5359 after oral dose of PAR-5359 at a dose of 1 mg/kg to male SD rats.

참고문헌 (Reference)

1 Matuszewski, B. K., "Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/ MS" 75 : 3019-3030, 2003

2 Korfmacher, W. A., "Principles and applications of LC-MS in new drug discovery" 10 : 1357-1367, 2005

3 Balakumar, P., "PPAR dual agonists: are they opening Pandora’s Box?" 56 : 91-98, 2007

4 Kim, M. K., "PAR-5359, a well-balanced PPARα/γ dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo" 595 : 119-125, 2008b

5 Paek, B., "Metabolism of a new P-glycoprotein inhibitor HM-30181 in rats using liquid chromatography/electrospray mass spectrometry" 20 : 1457-1462, 2006

6 Lee, H. W., "Hydrophilic interaction" 32 : 2353-2358, 2009

7 White, R. E., "High-throughput screening in drug metabolism and pharmacokinetic support of drug discovery" 40 : 133-157, 2000

8 Hsieh, Y., "HPLC-MS/MS in drug metabolism and pharmacokinetic screening" 4 : 93-101, 2008

9 Watts, G. F., "Fibrates, dysliporoteinaemia and cardiovascular disease" 10 : 561-574, 1999

10 Chaput, E., "Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight" 271 : 445-450, 2000

11 Ji, H. Y., "Determination of gabapentin in human plasma using hydrophilic interaction liquid chromatography with tandem mass spectrometry" 20 : 2127-2132, 2006

12 Kim, E., "Design, synthesis, and evaluation of novel aryl-tetrahydropyridine PPARα/γ dual agonists" 18 : 4993-4996, 2008a

13 Han, H. O., "Design and synthesis of oxime ethers of alpha-acyl-beta-phenylpropanoic acids as PPAR dual agonists" 17 : 937-941, 2007